title: Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone.
abstract: Solitary plasmacytoma of bone (SPB) is a rare tumor that represents a minority of patients with plasma cell localized malignancy characterized by a single osteolytic bone lesion. The molecular mechanism underlying the genesis of SPB has remained enigmatic. Signal transducers and activators of transcription-3 (STAT3) is often activated in human cancers and is implicated in tumorigenesis. In the present work, the immunohistochemical expression of pSTAT3 (the active isoform of STAT3) and its potential downstream mediators (Bcl-2, Bcl-xL, c-Myc, cyclin D1, VEGF, cIAP-2, Mcl-1, and survivin) were examined, clinical features were investigated, and relative prognostic factors were analyzed. Positive expression of Bcl-2 was observed in 46.7 % (14/30) of patients, c-Myc in 36.7 % (11/30), and cyclin D1 in 23.3 % (7/30). By univariate analysis, Bcl-2 expression was found to be closely associated with shorter overall survival (OS) and progression-free survival. Bcl-2 and c-Myc positive expression were also found to be a factor that affect time to progression to multiple myeloma. In conclusion, results showed Bcl-2 expression to be a clinically significant prognostic indicator for SPB patients and constitutive activated STAT3 may not be the sole primary regulatory mechanism.
authors.affiliation: Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, People's Republic of China, shanqi.guo@gmail.com.
authors.forename: Shanqi
authors.initials: S
authors.lastname: Guo
authors.forename: Yaqin
authors.initials: Y
authors.lastname: Zhi
authors.forename: Hongliang
authors.initials: H
authors.lastname: Yang
authors.forename: Yong
authors.initials: Y
authors.lastname: Yu
authors.forename: Yafei
authors.initials: Y
authors.lastname: Wang
authors.forename: Jin
authors.initials: J
authors.lastname: Zhang
authors.forename: Guowen
authors.initials: G
authors.lastname: Wang
authors.forename: Lianyu
authors.initials: L
authors.lastname: Zhang
authors.forename: Baocun
authors.initials: B
authors.lastname: Sun
authors.forename: Yizhuo
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D015331:Cohort Studies; D019938:Cyclin D1 / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000209:etiology; D009363:Neoplasm Proteins / Q000378:metabolism; D010954:Plasmacytoma / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D012189:Retrospective Studies; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C530104:CCND1 protein, human; C489427:MYC protein, human; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D019938:Cyclin D1